Quantcast
Last updated on April 18, 2014 at 16:58 EDT

Latest immunotherapy Stories

2014-04-11 13:01:17

Significant new data presented today at the International Liver Congress™ 2014 indicate that liver cancer (Hepatocellular Carcinoma (HCC)) may be treated by adoptive T-cell therapy. This new therapeutic approach in the treatment of HCC could be very important as without treatment the 5 year survival rate is just 5%. Globally, HCC accounts for 746,000 deaths, and in the UK alone is responsible for over 4,000 deaths per year. Glypican-3 (GPC3) is a tumor associated antigen expressed in...

2014-04-11 10:56:48

In experiments with mice, Johns Hopkins Kimmel Cancer Center scientists have identified an enzyme involved in the regulation of immune system T cells that could be a useful target in treating asthma and boosting the effects of certain cancer therapies. In research described online April 6 in Nature Immunology, the investigators show that mice without the enzyme SKG1 were resistant to dust mite-induced asthma. And mice with melanoma and missing the enzyme, developed far fewer lung...

2014-04-07 16:25:44

Largest-ever gift to the Hutch promises to save lives by broadening the application of immunotherapy to lung, ovarian, pancreatic and colon cancers SEATTLE, April 7, 2014 /PRNewswire/ -- Fred Hutchinson Cancer Research Center scientists striving for new cancer cures -- and the patients who stand to benefit from them -- got an enormous boost today when the Bezos family committed $20 million to support the development of novel cancer immunotherapies. It is the largest single...

2014-04-07 04:21:10

ROCKLAND, Massachusetts, April 7, 2014 /PRNewswire/ -- - First patient dosed in tecemotide Phase III trial; study recruiting across 250 sites in over 20 countries - START2 builds upon the data from the START* trial and explores the potential of tecemotide in patients with Stage III NSCLC who have demonstrated stable disease or objective response after concurrent chemoradiotherapy EMD Serono,...

2014-04-04 23:27:07

Immunotherapy is one of the most exciting new approaches to treating cancer. Dr. Carl June will discuss his findings May 14 as featured speaker at UC San Diego. (PRWEB) April 04, 2014 A world leader in immunotherapy, Carl June, will discuss the emergence of a new form of targeted immunotherapy to treat cancer, Wednesday, May 14, 5:30 pm to 7 pm., at UC San Diego. June, professor of immunotherapy at the University of Pennsylvania, will discuss his pioneering work and also the barriers and...

Allergy Pill For Hay Fever Approved By FDA
2014-04-03 05:24:55

redOrbit Staff & Wire Reports - Your Universe Online In a move that could replace allergy shots for some men and women, the US Food and Drug Administration (FDA) announced on Wednesday that it had approved the first tablet for the treatment of hay fever symptoms. The product is known as Oralair, according to USA Today’s Kim Painter, it will only work against certain types of grass pollens and will take multiple months before it starts working – meaning that it will not help...

2014-04-02 23:32:49

Presentation details three separate tuberculosis immunotherapies developed by Immunitor in collaboration with academic institutions and private companies in Mongolia, China, Thailand, Ukraine, UK, USA and Canada. Data presented support the Immunitor strategy to target inflammation as the main cause of TB and development of immunomodulators and therapeutic vaccines which demonstrate ability to rapidly clear TB, including MDR-TB and TB with HIV. Vancouver, BC, Canada (PRWEB) April 02, 2014...

2014-04-02 08:32:13

Autologous Cells Modified with Licensed T Cell Receptor (TCR) IP from University of Pennsylvania Studied for Safety, Bioactivity, and Effectiveness to Treat Multiple Myeloma BOTHELL, Wash., April 2, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that Oxford, UK...

2014-04-01 04:20:52

Immunotherapy and Vaccine Leader Also Promotes Three Executives in Legal, Clinical and Investor Relations BLUE BELL, Pa., April 1, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced the appointment of E.J. Brandreth as Vice President of Quality. He will be responsible for all quality and compliance functions for a company that is moving forward with numerous late and early stage clinical trials and scaling up manufacturing and other operational areas to support...

2014-03-31 16:27:14

MONMOUTH JUNCTION, N.J., March 31, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses in the intensive care unit, provides an operational summary and financial results for the fiscal year ending December 31, 2013. Q1 2014 CytoSorb® product revenue guidance in the range of $530,000 - $570,000 represents more than 60% of total 2013 CytoSorb® revenues Highlights for the Year Ending...